, and

Motivation: The probability of effective treatment of cancer with a targeted therapeutic can be improved for patients with defined geno-types containing actionable mutations. To this end, many human cancer biobanks are integrating more tightly with genomic sequenc-ing facilities and with those creating and maintaining patient-derived xenografts (PDX) and cell lines to provide renewable resources for translational research. Results: To support the complex data man-agement needs and workflows of several such biobanks, we devel-oped Acquire. It is a robust, secure, web-based, database-backed open-source system that supports all major needs of a modern can-cer biobank. Its modules allow for 1) up-to-the-minute "scoreboard" and graphical reporting of collections; 2) end user roles and permis-sions; 3) specimen inventory through caTissue Suite; 4) shipping forms for distribution of specimens to pathology, genomic analysis and PDX/cell line creation facilities; 5) robust ad hoc querying; 6) molecular and cellular QC metrics to track specimens ’ progress and quality; 7) public researcher request; 8) resource allocation commit-tee distribution request review and oversight; and 9) linkage to available derivatives of specimen. Availability and Implementa-tion: Acquire implements standard controlled vocabularies, ontolo-gies and objects from the NCI, CDISC, and others. Here we de-scribe the functionality of the system, its technological stack and the processes it supports. A test version Acquire is available a